Join MySLAS Social

3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis

Read this Article

Tijmen H. Booij, Ph.D.
Screening Specialist
NEXUS Personalized Health Technologies
Zürich, Switzerland

 

Tijmen H. Booij, Ph.D., studied bio-pharmaceutical sciences at Leiden University (Leiden, the Netherlands). As part of his studies, Booij jointly developed a 3D high-content screening platform at the Leiden Academic Center for Drug Research (LACDR, Leiden, the Netherlands) and OcellO B.V. (Leiden, the Netherlands) for which he received the Suzanne Hovinga Award. Upon graduating cum laude, he was appointed as a Ph.D. candidate at the LACDR to develop 3D cell culture-based high-throughput and high-content screening methodology for polycystic kidney disease (PKD) and various neoplastic disorders in a collaborative effort with the Leiden University Medical Center (LUMC, Leiden, the Netherlands) and OcellO B.V. Booij presented his work at multiple international scientific conferences (SLAS Tony B. Academic Travel Award 2013 and 2016) and published his work in several scientific journals.

Since obtaining his Ph.D. degree in 2017, Booij works at NEXUS Personalized Health Technologies, a technology platform of ETH Zürich (Zurich, Switzerland), as a laboratory automation and screening specialist, where he is driving, and developing, 3D cell culture and organoid-based screening projects. His main interests are in high-content and high-throughput screening with advanced cell culture assays in the context of neoplastic disorders as well as in high-throughput microscopy and image analysis – ultimately aiming to contribute to the discovery of novel therapeutics.

Website
LinkedIn

SLAS Publications

3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis and High-Content Analysis

High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease

Development of a 3D Tissue Culture-Based High-Content Screening Platform that Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases


SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members.  > READ MORE

June 20, 2019